Acuitas Therapeutics Inc. (“Acuitas”) has initiated legal action against CureVac, filing a Complaint on November 13 in the U.S. District Court for the Eastern District of Virginia. It is alleged that CureVac incorrectly claimed inventorship of four U.S. Patents related to COVID-19 mRNA-LNP vaccines that are registered under their name. Specifically, the patents in question are U.S. Patent Nos. 11,241,493, 11,471,525, 11,576,966, and 11,596,686, together known as the “’493 Patent Family.”
For legal professionals, particularly those working in corporate or patent law, this case represents an important event to monitor. Not only does it encompass the nuanced area of patent and inventorship disputes, but it also falls within the context of the global COVID-19 pandemic where the development of vaccines and related technologies encompasses significant stakes.
Acuitas’s challenge to CureVac over these patents could potentially have important implications for corporate rights and the broader pharmaceutical industry. The intricacies of patent law make the outcome far from certain, and detailed deliberation on legal principles and patent validity will likely be required by the court.
For those interested in further delving into the specifics of this matter, the full complaint filed by Acuitas against CureVac is accessible here.